Emcure Pharmaceuticals announced the commercial launch of Poviztra®, semaglutide injection, across India. With this launch Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra®, a second brand of Novo Nordisk's Semaglutide injection for weight management. Available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dosing of 2.4 mg, the products will be priced starting Rs 8790/- per month (4 weekly doses). It comes in a state-of-the-art pen device that provides the convenience of simple administration of precise dosing.
Semaglutide injection (Poviztra®) is supported by extensive clinical evidence from the STEP and SELECT clinical trial programmes and has demonstrated robust real-world use. Globally, the molecule has nearly a decade of market presence, 38 million patient-years* of exposure, and a strong safety and efficacy profile backed by comprehensive data.
Poviztra® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). Poviztra® is also indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight. In clinical trials, the semaglutide formulation achieved weight loss of more than 20% in many patients.